Health Canada approves the first generic version of semaglutide for weight loss, introducing a new once-weekly injectable option in Canada. Multiple reports say the product is made by Apotex and is sold under the brand name Svemia. It is described as a generic alternative to Wegovy, the brand-name semaglutide medicine made by Novo Nordisk. The approval covers use for people aged 12 and older and follows Health Canada’s assessment for the treatment of weight-related conditions. The approval is notable because it provides an additional source of semaglutide specifically authorized for weight management, potentially expanding access compared with the original brand-name product. The reports characterize the medicine as intended for regular, once-a-week dosing rather than daily use, aligning with the established Wegovy regimen. The outlets do not indicate any separate new indication beyond weight loss authorization, and they frame the decision primarily as the first Canadian approval for a generic semaglutide injection for this purpose.